News

Keep up with the latest headlines in dermatology from the past week, including one dermatologist's journey with vascular birthmarks, award recipients, and more.

ICYMI, this week we had news about COVID-19 research and dermatology, Journey Medical's accepted NDA for DFD-29, late-breaking data on amlitelimab for AD, and more.

If approved, bimekizumab will be the first IL-17A and IL-17F inhibitor approved in Europe for hidradenitis suppurativa.

The paper was authored and issued by the FDA Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, and Office of Combination Products.

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

Researchers developed a VR scenario skin cancer screening involving technical realization, curricular integration, and an evaluation of the subjective learning experience and teaching concept.

Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.

Two recently published studies evaluated the uses of and attitudes toward telehealth in dermatology after the COVID-19 pandemic.

Late-breaking data demonstrating the sustained improvements was presented at the American Academy of Dermatology Annual Meeting.

Dermatology Times recently spoke with Latanya Benjamin, MD, FAAD, FAAP, the newly-appointed president of the WDS, to discuss her hopes and goals for her presidency.

Two posters at the AAD Annual Meeting examined disparities in skin cancer survival between urban and rural areas and assessed how having skin of color affects this.

The recommendations were recently published in JAMA Dermatology following an extensive literature review, article grading, and a review of research questions.

The statement said the petition came as a surprise to many ahead of AAD, and delves into the data complexity and patient considerations.

We take a look at various studies examining the role of artificial intelligence in telemedicine photo quality, the impact of the COVID-19 pandemic and skin cancer diagnoses, and more.

In this week’s Pointers With Portela, the 208SkinDoc dives into the efficacy and adverse effects of generic vitamin A to treat acne.

While additional, larger studies are necessary, researchers said dietary choices may help reduce dependency on pharmacological methods.

We spoke with several dermatology experts to gauge their thoughts on Valisure's recent findings of benzene in benzoyl peroxide products--as well as what actions they plan to take moving forward.

In her March edition of Cosmetic Conundrums, Zoe Diana Draelos, MD, explores the role of exosomes in aesthetic dermatology, changes in the skin, and more.

We take a look at various studies exploring the relationship between psoriasis and COVID-19 vaccination, the link between COVID-19 and psoriasis severity, and more.

AI mobile apps have critical gaps in efficacy, safety, and transparency, according to a new report.

Den, the chief medical officer of Alpha Tau, discusses the alpha particle-emitting atom treatment and its ability to target cancer cells without harming healthy tissue.

The expanded approval of Spevigo follows the Chinese National Medical Products Administration’s approval for the injection for the reduction of occurrence of GPP.

The FDA has assigned a Prescription Drug User Fee Act target action date for August 13.

The social and psychological effects of vitiligo, particularly concerning gender disparities, have come to the forefront in recent literature.

Two recent studies delve into outcomes of pediatric populations with atopic conditions and an overview of patient outcomes utilizing a Mendelian randomization analysis.

On March 6, 2024, Valisure, an independent testing laboratory, found high levels of benzene when BPO products were incubated at 37°C, 50°C, and 70°C.

From our March cover feature: Vulnerable populations such as the prison population should have access to Mohs surgery to prevent the increased risk of morbidity and mortality from skin cancer.

The anticipated PDUFA date is November 4, 2024.

It has been 4 years since the COVID-19 pandemic began. In the time since, there has been plentiful research regarding its implications in dermatology.

The data suggests that the medication, which targets specific cellular pathways, promotes hair regrowth in AA with minimal adverse effects.